Flagship Pioneering, the US venture firm behind Moderna, will put £100 million ($131.94 million) into building AI-driven biotech companies in Britain

1

. The commitment funds a new company-creation lab anchored at the firm's London office, announced on November 16

1

.

It is the first company-creation lab Flagship has opened outside the United States after more than 25 years in which it operated only in the US

1

. Flagship has built more than 130 companies over that run, including Moderna, the mRNA drug maker that made the firm's name

2

.

Why Britain

Noubar Afeyan, Flagship's founder and CEO and Moderna's chairman, said the National Health Service and its accumulated patient data are the country's main draw

1

. Real-world patient records let researchers start from evidence about disease to find drug targets, rather than the other way around

1

.

Flagship's portfolio company Generate Biomedicines has already run the approach in Britain, completing an early-stage trial in Manchester of an asthma drug designed with AI

2

.

The lab is also the product of three years of groundwork. Flagship set up its London office in 2023, beside the Francis Crick Institute in King's Cross. The team there has since built partnerships with academia, government bodies and regulators

1

.

How the lab will work

The plan is company creation from scratch. Flagship will not buy into existing companies; it plans partnerships with universities, corporations and funders instead

1

. It expects to hire roughly 50 scientist-entrepreneurs and operators in Britain to start

2

.

The £100 million is the opening commitment. Afeyan said Flagship hopes the money will pull in £500 million or more from partners

1

, though that figure is an aspiration rather than secured cash

1

. Afeyan said the firm concluded the move might well prove the right next step in its evolution

1

.

AI, per Afeyan, will be part of everything the lab does, from inventing drugs to running trials

1

. But he cautioned that AI's use in the field is at an early stage

2

. "We're in an age where I think AI's most fundamental contribution in the first instance will be to shed a light on actually what's happening mechanistically in diseases," Afeyan said

1

.

© 2026 TheOutpost.AI All rights reserved